


Accepted Manuscript

Bovine milk oligosaccharides as anti-adhesives against the respiratory tract pathogen *Streptococcus pneumoniae*

Joseph Thomas Ryan, Helen Slattery, Rita M. Hickey, Mariarosaria Marotta



PII: S0958-6946(18)30040-2

DOI: [10.1016/j.idairyj.2018.02.002](https://doi.org/10.1016/j.idairyj.2018.02.002)

Reference: INDA 4276

To appear in: *International Dairy Journal*

Received Date: 5 May 2017

Revised Date: 8 February 2018

Accepted Date: 9 February 2018

Please cite this article as: Ryan, J.T., Slattery, H., Hickey, R.M., Marotta, M., Bovine milk oligosaccharides as anti-adhesives against the respiratory tract pathogen *Streptococcus pneumoniae*, *International Dairy Journal* (2018), doi: 10.1016/j.idairyj.2018.02.002.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 **Bovine milk oligosaccharides as anti-adhesives against the respiratory tract pathogen**

2 *Streptococcus pneumoniae*

3

4

5

6

7

8 Joseph Thomas Ryan^a, Helen Slattery^b, Rita M. Hickey^b, Mariarosaria Marotta^{a,*}

9

10

11

12

13

14

15 ^a *Food for Health Ireland, Teagasc Food Research Centre, Moorepark, Fermoy, Co. Cork,*

16 *Ireland*

17 ^b *Food Biosciences Department, Teagasc Food Research Centre, Moorepark, Fermoy, Co.*

18 *Cork, Ireland*

19

20

21

22

23

24 *Corresponding author. Tel.: +353 25 42438

25 *E-mail address:* mariarosaria.marotta@teagasc.ie (M. Marotta)

26

27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

ABSTRACT

Streptococcus pneumoniae is a Gram-positive pathogen, which is regularly found in the upper respiratory tract of healthy individuals. Increased numbers of *S. pneumoniae* have been observed colonising the upper respiratory tract of children affected by respiratory tract infections. Gal β 1-4GlcNAc β 1-3Gal has been previously identified as one of the receptors involved in the adherence and translocation of *S. pneumoniae*. As this structure is similar to the milk oligosaccharide lacto-N-neoTetraose, many studies have investigated if free milk oligosaccharides can inhibit the adhesion of *S. pneumoniae* to epithelial cells of the respiratory tract. Here, we demonstrate that bovine oligosaccharides, which were extracted from demineralised whey, using a combination of membrane filtration and chromatography, were capable of reducing *S. pneumoniae* adhesion to pharynx and lung cells in vitro when tested at physiological concentrations. This study strengthens the potential use of bovine derived milk oligosaccharides as functional ingredients to reduce the incidence of infectious diseases.

51 1. Introduction

52

53 Respiratory tract infections (RTI) account for almost half of all general practitioner
54 and hospital visits by infants and young children (Bachrach, Schwarz, & Bachrach, 2003).
55 The most common infections include acute otitis media, sinusitis and bronchitis. In general,
56 RTI are caused by either viral or bacterial pathogens and very often as a combination of both.
57 Bacteria frequently associated with respiratory tract infections include *Streptococcus*
58 *pneumoniae*, *Haemophilus influenzae*, *Moraxella catarrhalis*, and *Staphylococcus aureus*
59 (Bosch, Biesbroek, Trzcinski, Sanders, & Bogaert, 2013; Pettigrew, Gent, Revai, Patel, &
60 Chonmaitree, 2008).

61 *Streptococcus pneumoniae* is a Gram positive pathogen, which regularly colonises the
62 upper respiratory tract (URT) of healthy individuals. Carriage of *S. pneumoniae* is typically
63 asymptomatic in nature (Bogaert, de Groot, & Hermans, 2004). However, if this bacterium
64 gains access to the sterile parts of the respiratory tract, the result is a swift inflammatory
65 response, which in turn causes disease. Elevated *S. pneumoniae* colonisation has been
66 recorded in the URT of children suffering from RTI (García-Rodríguez & Martínez, 2002).
67 Furthermore, the colonisation of the respiratory tract by *S. pneumoniae* reduces the microbial
68 diversification of the host; this, in turn, has been linked to an increased risk of respiratory
69 infections. Infections of the lower respiratory tract of infants and young children is also a
70 matter of great importance, as pneumonia is one of the leading causes of global infant
71 mortality. In fact, greater than 30% of pneumonia related deaths are caused by *S. pneumoniae*
72 (Rudan, Boschi-Pinto, Biloglav, Mulholland, & Campbell, 2008).

73 To cause infection, *S. pneumoniae* must first adhere to human nasopharyngeal
74 epithelial cells. One of the receptors responsible for the attachment of *S. pneumoniae* to
75 human nasopharyngeal epithelial cells is GlcNAc β 1-3Gal (Andersson & Svanborg-Eden,

76 1989). This receptor shares similarity with the oligosaccharide lacto-N-neoTetraose, Gal β 1-
77 4GlcNAc β 1-3Gal β 1-4Glc (LNnT) (Idänpään-Heikkilä et al., 1997). In this respect, several
78 studies have demonstrated that synthesised oligosaccharides (OS) inhibit the adhesion of *S.*
79 *pneumoniae* to epithelial cells of the respiratory tract. For instance, the pre-exposure of *S.*
80 *pneumoniae* to LNnT and its α 2-6-sialylated derivative reduced the pneumococcal load in the
81 lungs of animal models (Idänpään-Heikkilä et al., 1997). Furthermore, LNnT was reported to
82 inhibit the adherence of *S. pneumoniae* to the receptor Gal β 1-4GlcNAc β 1-3Gal (Tong,
83 McIver, Fisher, & DeMaria, 1999). LNnT also provided a protective effect against *S.*
84 *pneumoniae* by preventing pneumonia in rabbits (Idänpään-Heikkilä et al., 1997). Sialylated
85 oligosaccharide ligands terminating in NeuAc α 2-3(or 6)Gal β 1 were demonstrated to reduce
86 the adhesion of *S. pneumoniae* to human bronchial and tracheal cells (Barthelson, Mobasseri,
87 Zopf, & Simon, 1998). These studies strongly suggest that free OS such as LNnT, 3'SLNnT,
88 6'SLNnT, can prevent the adhesion of *S. pneumoniae* to human epithelial cells. These OS
89 and several other complex OS are naturally found in breast milk (Kunz, Rudloff, Baier, Klein
90 & Strobel, 2000). In fact, it is known that infants those who are exclusively breastfed have a
91 lower incidence of RTI (Wright, Holberg, Martinez, Morgan, & Taussig, 1989).

92 However, the protective effects ascribed to human milk oligosaccharides (HMO) are
93 not available to formula-fed infants. Infant milk formulas are based on bovine milk, which
94 contains a lower concentration of bovine milk oligosaccharides (BMO; $\sim 0.03 \text{ g L}^{-1}$)
95 compared to OS in human milk (10–15 g L^{-1} ; Kunz et al., 2000). A number of BMO do,
96 however, share the same structure as certain HMO, which could imply common
97 functionalities (Barile et al., 2009; Mariño et al., 2011). Therefore, value may lie in extracting
98 and concentrating BMO with a view to their addition as an active ingredient to infant
99 formulas. In a recent pilot study (Mehra et al., 2014), a powder enriched in BMO was
100 produced through a membrane filtration process using mother liquor as a starting material. In

101 the current study, this method was used to generate an enriched-BMO powder from
102 demineralised whey powder, which is an important ingredient in infant formula manufacture.
103 The powder was further depleted in lactose through size-exclusion chromatography. The final
104 powder, which was enriched in BMO, was examined for its ability to prevent adhesion of *S.*
105 *pneumoniae* to respiratory cells using in-vitro assays.

106

107 **2. Materials and methods**

108

109 *2.1. Materials*

110

111 Tissue culture reagents were purchased from Sigma–Aldrich (Wicklow, Ireland) and
112 LGC (Middlesex, United Kingdom). The oligosaccharides 3'-sialyllactose and 6'-sialyllactose
113 (3-SL and 6-SL, respectively) were purchased from Carbosynth, Compton, UK. The purity of
114 both 3-SL and 6-SL is a minimum 98% according to the company's specification.

115

116 *2.2. Enrichment of oligosaccharides*

117

118 For enrichment of OS, demineralised whey powder, purchased from Dairygold Co-
119 Operative Society Ltd (Mitchelstown, Ireland), was used in a joint project between Teagasc
120 and University of California, Davis to enrich OS, according to Mehra et al. (2014). Starting
121 with demineralised whey powder, which was re-suspended in water to give a final volume of
122 2428 L at 5% total solids, the process yielded 2.5 kg of milk oligosaccharide-rich powder
123 (OSP), which was transferred to the Food for Health Ireland consortium and used in the
124 present study, with the agreement of University California, Davis.

125 For testing OS in biological assays, OSP was further treated to remove residual

126 peptides and large levels of lactose. 50 mL of a 20% solution of the OSP was applied to a

127 BioGelP2 size exclusion column (Bio-rad Laboratories, Inc., USA; 92 × 5 cm) and eluted
128 with deionised water at a flow rate of 3 mL min⁻¹. The fractions (14 mL) were analysed for
129 lactose, 3-SL and 6-SL using high pH anion exchange chromatography with pulsed
130 amperometric detection (HPAEC-PAD) and peptide concentration (Bradford, 1976). Peptide-
131 free and low-trace lactose fractions (< 80 mg L⁻¹) from 15 runs were pooled and freeze-dried
132 to give an oligosaccharide-rich fraction (OSF).

133

134 2.3. *Quantification of lactose and sialyllactose by high performance liquid* 135 *chromatography*

136

137 Demineralised whey powder, OSP, OSF and fractions from BioGelP2 were
138 appropriately diluted in water and analysed for quantification of lactose, 3-SL and 6-SL.
139 Lactose in demineralised whey powder, OSP and OSF was quantified by high performance
140 liquid chromatography (HPLC) using an HPX-87C carbohydrate column (300 × 7.8 mm)
141 (Aminex, Bio-Rad, UK) and a refractive index detector. The elution was obtained in isocratic
142 conditions using 4.5 mM sulphuric acid for 30 min. 3-SL and 6-SL in all samples above and
143 lactose in fractions from BioGelP2 were quantified by HPAEC-PAD, according to Mehra et
144 al. (2014).

145

146 2.4. *Structural characterisation of milk oligosaccharides*

147

148 The free OS in the OSF were structurally characterised by hydrophobic interaction
149 liquid chromatography (HILIC) coupled to mass spectrometry by the National Institute for
150 Bioprocessing Research & Training (NIBRT, Dublin, Ireland) as described by Mariño et al.
151 (2011).

152

153 2.5. *Organisms and growth conditions*

154

155 The *S. pneumoniae* strain ATCC BAA-255 (*S. pneumoniae* R6) was obtained from
156 the American Type Culture Collection. *S. pneumoniae* R6 was stored in Todd Hewitt broth
157 (Becton Dickinson and Company, France) containing 10% (v/v) glycerol at $-80\text{ }^{\circ}\text{C}$ and
158 cultured directly from storage into the same broth with 0.5% (w/v) yeast extract (0.2%
159 inoculum) at $37\text{ }^{\circ}\text{C}$ with 5% CO_2 until an optical density (600 nm) of 0.8 was reached.

160

161 2.6. *Culture of pneumocytes*

162

163 Adherent Detroit 562 (pharynx) and A549 (lung) cells were purchased from the
164 American Type Culture Collection. These cell lines were chosen because of their routine use
165 in previous studies (Jensch et al., 2010; Kallio et al., 2014). The Detroit 562 cells were grown
166 in Eagle's Minimum Essential Medium (EMEM) supplemented with 10% (v/v) foetal bovine
167 serum (FBS) and 1% (w/v) of penicillin-streptomycin. The A549 cells were grown in
168 Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) of FBS and
169 1% (w/v) of penicillin-streptomycin. Cells were incubated at $37\text{ }^{\circ}\text{C}$ in an atmosphere of 5%
170 CO_2 and passaged every 3–4 days at ratio 1:6. When the cells were used in the adhesion
171 assay, they were washed twice with PBS and then incubated with 0.25% trypsin/EDTA
172 solution. Trypsination was stopped by adding 8–10 mL of fresh antibiotic-free medium. After
173 seeding cells in 12-well plates to a density of 5×10^5 per well, they were incubated overnight,
174 and then the spent medium was replaced with 1 mL of DMEM or EMEM supplemented with
175 2% (v/v) FBS. After a further overnight incubation as described above, the cells were used in
176 the adhesion assay.

177

178 2.7. *Adhesion assay*

179

180 The adhesion assay used in the present study was adapted from previous publications
181 (Marotta, Ryan, & Hickey, 2014). Prior to the adhesion assay, confluent monolayers were
182 treated with 5 $\mu\text{g mL}^{-1}$ interleukin 1 β for 4 h at 37 °C with 5% CO₂ to mimic host cell
183 response during infection (Rosenow et al., 1997). Briefly, 6 mg mL⁻¹ solutions of
184 demineralised whey powder and OSP were prepared in EMEM supplemented with 2% (v/v)
185 FBS. Solutions of OSF were prepared at the following concentrations: 6 mg mL⁻¹, 4 mg mL⁻¹,
186 2.4 mg mL⁻¹, 2 mg mL⁻¹, 1.15 mg mL⁻¹ and 0.24 mg mL⁻¹ (corresponding to 0.3, 0.2, 0.125,
187 0.1, 0.0575 and 0.0125 mg mL⁻¹ of 6-SL in OSF, respectively) in the appropriate medium
188 supplemented with 2% FBS (v/v). All solutions were sterilised by filtration. Bacteria were
189 harvested and re-suspended in tissue culture media with or without OS at 1×10^6 colony
190 forming units (cfu) mL⁻¹ and incubated for 30 min at 37 °C in an atmosphere of 5% CO₂ (pre-
191 incubation step). Controls with no saccharide were also prepared. Confluent monolayers in
192 12-well plates were washed with PBS, infected with 1 mL of pre-incubated bacteria and
193 incubated for 30 min at 37 °C with 5% CO₂. After 30 min incubation, the wells were washed
194 three times with PBS to remove any non-adherent bacteria and lysed with 1 mL of PBS
195 containing 0.2 % (v/v) Triton X-100 (Sigma, Steinheim, Germany) for 30 min at 37 °C on a
196 shaking platform at 100 agitations per min to ensure maximal recovery of viable bacterial
197 cells. The lysates were serially diluted and enumerated by spread-plating on sheep blood agar
198 plates. Aliquots of the experimental inocula were retained, diluted and plated to determine
199 original cfu mL⁻¹. Agar plates were incubated at 37 °C with 5% CO₂ overnight after which
200 cfu were enumerated.

201

202 2.7. *Bacterial interaction*

203

204 In an effort to determine if OS interact with bacteria, the adhesion assay was slightly
205 modified. *S. pneumoniae* R6 was grown as described above, re-suspended (1×10^6 cfu mL⁻¹)
206 in an OSF solution at a concentration of 6 mg mL⁻¹ and 2.4 mg mL⁻¹ when working with
207 Detroit 562 and A549 cells, respectively, in the appropriate medium supplemented with 2%
208 FBS (v/v) and incubated for 30 min at 37 °C 5% CO₂. The samples were centrifuged at 4000
209 × *g* for 7 min to pellet the bacterial cells. The medium containing unbound oligosaccharides
210 was removed and the bacterial pellet was re-suspended in an equal volume of appropriate
211 medium. Following this the adhesion assay was performed as described above.

212

213 2.8. *Cell line interaction*

214

215 To determine if OS mixture interacts with epithelial cells, the adhesion assay was
216 modified. Confluent monolayers of Detroit 562 and A549 cells were washed with PBS and
217 supplemented with 1 mL of OSF solution at a concentration of 6 mg mL⁻¹ (Detroit 562) and
218 2.4 mg mL⁻¹ (A549) in the appropriate medium supplemented with 2% FBS (v/v). Controls
219 were performed in the absence of saccharides. The 12 well plates were incubated at 37 °C 5%
220 CO₂ for 30 min. Following incubation, the 12 well plates were washed 5 times with PBS to
221 remove the unbound OS. The confluent monolayers were then infected with 1 mL *S.*
222 *pneumoniae* R6 (1×10^6 cfu mL⁻¹) resuspended in the appropriate medium supplemented
223 with 2% FBS (v/v) and incubated for 30 min. To determine the amount of adhering bacteria
224 the adhesion assay was performed as described above.

225

226 2.9. *Statistical analysis*

227

228 The adhesion assays were carried out on three separate occasions in triplicate. Results
229 are presented as mean \pm standard deviations of replicate experiments. Graphs were drawn
230 using Microsoft Excel and the unpaired student t-test was used to determine statistically
231 significant results; $P < 0.05$ was considered significant.

232

233 **3. Results and discussion**

234

235 It is widely accepted that human milk protects and promotes infant health (Gartner et
236 al., 2005). For instance, human milk plays a major role in protecting infants from respiratory
237 infections (Duijts, Ramadhani, & Moll, 2009; Wright et al., 1989). Recently, in addition to
238 IgA, free HMO have been implicated in this protective role, which may be exerted through
239 direct and/or indirect effects (Stepans et al., 2006). As direct effect, HMO may interfere with
240 adhesion, by acting as decoys to which pathogens can bind. In the URT, the frequent bathing
241 in milk might modulate the adherence of bacteria to epithelial cells through the high
242 concentration of OS present, thereby reducing the incidence of harmful organisms and
243 lowering the risk of infection (Barthelson et al., 1998). In the lower respiratory tract, OS may
244 reach the respiratory epithelia through absorption into the blood stream, where they could
245 influence bacterial-host interactions in a similar manner as observed in the gut. In this
246 respect, Goehring, Kennedy, Prieto, and Buck (2014) have demonstrated that some ingested
247 HMO are absorbed intact into the infant circulation. In terms of indirect effects, specific
248 HMO may have effect on the immune system, as demonstrated by numerous in vitro studies
249 (Bode et al., 2004a; Bode, Rudloff, Kunz, Strobel, & Klein, 2004b; Eiwegger et al., 2010).

250 As *S. pneumoniae* is one of the major bacterial etiological agents of respiratory tract
251 infections in infants and children, we focused our attention on investigating the effect of a

252 pool of oligosaccharides on adhesion of *S. pneumoniae* on respiratory cells of both the upper
253 and lower respiratory tract. As human milk is not available for commercial purposes, bovine
254 milk streams were considered as a suitable source of OS, given their widespread availability.

255

256 3.1. *Enrichment of oligosaccharides*

257

258 As previously mentioned, concentrations of OS in bovine milk and its streams are
259 much lower than concentrations of OS found in human milk. For this reason, before testing
260 the biological properties of BMO, they were extracted and concentrated from demineralised
261 whey. Demineralised whey was selected as starting material for OS enrichment, because it
262 contains a higher concentration of sialyllactose (SL, 3'- and 6'- sialyllactose) (47 mg L^{-1}) for
263 similar lactose concentration (48 g L^{-1}) compared with bovine milk. Furthermore,
264 demineralised whey is characterized by lower mineral levels, which may be advantageous for
265 applications in infant formula manufacture, when compared to other bovine streams with
266 similar SL and lactose concentrations (such as whey permeates). To evaluate enrichment of
267 OS through the process, SL was selected as a marker of total OS, since it is the predominant
268 oligosaccharide in the BMO pool and can be quantified by using routine analytical methods.

269 Following membrane filtration and diafiltration, the diafiltered OS-enriched retentate
270 had a SL to lactose ratio of 1.65%. This represents a 17-fold enrichment of SL based on the
271 SL/Lactose ratio. Upon evaporating and spray drying the retentate, 2.5 kg of a powder (OSP)
272 was obtained with the following composition: 70.21% (w/w) lactose, 1.20% (w/w) SL, 24.5%
273 (w/w) protein and 4.41 % (w/w) ash. Despite the enrichment of OS compared to the initial
274 demineralized whey, the major component of the OSP was still lactose. As it has been
275 previously demonstrated that lactose can interfere with the ability of oligosaccharides to
276 influence bacterial adhesion (Kavanaugh et al., 2013), to further reduce lactose and

277 concentrate OS, the OSP was applied to a size-exclusion chromatography, resulting in 8.83 g
278 of OSF.

279 The chromatographic step removed most of the lactose, while retaining approximately
280 71% of SL (Table 1), resulting in a powder with lactose and SL concentration (ratio 3-SL:6-
281 SL was 3.5:1) of 0.9% and 23% (w/w), respectively. Compared with concentrations found in
282 whey (0.07%, w/w; Marotta et al. unpublished data), this represents an approximate 329 fold
283 SL enrichment in the OSF. Recently, nanofiltration was investigated to enrich BMO from
284 lactose-hydrolysed bovine milk (Altmann et al., 2015) and lactose-hydrolysed colostrum
285 whey permeate (Cohen, Barile, Liu, & de Moura Bell, 2017). Altmann et al. (2015) produced
286 a NF retentate containing 873.23 BMO mg L⁻¹. However, the data reported did not allow
287 calculation of the concentration of BMO as percentage of total solid. Cohen et al. (2017)
288 produced a NF retentate containing 5.96 SL g L⁻¹, which represented 6.7% of total solids.

289 Although the process employed in the present study did not hydrolyse lactose and did
290 not employ NF, as in Altmann et al. (2015) and Cohen et al. (2017), the OSF was
291 characterised by a much higher content of SL (23%, w/w). The oligosaccharide profile of the
292 OSF was analysed by NIBRT. After fluorescently labelling with 2-Aminobenzamide (2AB),
293 the sample was analysed by HILIC. A total of 29 peaks were detected and assigned
294 comparing the Glucose Unit (GU) values obtained with GU values previously published
295 (Mariño et al., 2011). Predominant peaks were 3-SL and 6-SL (taken together 55.2% of total
296 peak area), GalNAc(α 1-3)Gal(β 1-4)Glc (23.8% of total peak area) followed by Gal(α 1-
297 3)Gal(β 1-4)Glc (9.6% of total peak area), with latter two not being found in breast milk
298 (Urashima, Messer & Oftedal, 2017), despite the fact that neutral OS represent the highest
299 percentage of HMO (Kunz et al., 2000).

300 In addition, the sample was analysed by HILIC coupled to mass spectrometry for
301 structural assignment. This allowed the identification of 19 structures, ranging between 300

302 and 1200 Da. Five out of 19 structures (3'-fucosyllactose, 3-SL, 6-SL, 6'-sialyllactosamine
303 and LNnT, which account for a total peak area of 56.52%) are also found in breast milk
304 (Table 2). Furthermore, using the same analytical technique as Mariño et al. (2011), 4
305 structures were detected in the OSF, which were not reported in that study and these
306 included: 3'-fucosyllactose, NeuAc(α 2-3)Gal(β 1-3)Gal(β 1-4)Glc and the *O*-acetylated forms
307 of two sialylated oligosaccharides (NeuAc(α 2-3)Gal(β 1-4)Glc and NeuAc(α 2-8)NeuAc(α 2-
308 3)Gal(β 1-4)Glc). Finally, only a small proportion (0.4% of total peak area) of Neu5Gc was
309 detected in the OSF, which is particularly important for applications in infant formulas as
310 Neu5Gc [present in numerous mammals, but not in humans (Varki & Marth, 1995)], is
311 known to be antigenic (Varki & Schauer, 2009). To the best of our knowledge, this is the first
312 time that such a well characterised SL-enriched powder, which also contains a variety of
313 other OS structures, has been produced from commercial dairy streams.

314

315 3.2. *Effect of BMO on interaction between respiratory cells and S. pneumoniae*

316

317 To determine the concentration of the OSF that should be tested in the in vitro assays,
318 a number of options were considered such as adding an amount of powder equivalent to the
319 concentration of HMO (10–15 g L⁻¹). However, as the OSF is not a pure mixture of BMO, a
320 concentration of BMO corresponding to physiological concentrations of 6-SL, which is a
321 predominant acidic oligosaccharide in breast milk was selected. Furthermore, previous
322 studies demonstrated the importance of the α 2-6 linkage on interactions with bacteria
323 (Kavanaugh et al., 2013; Marotta et al., 2014). Marotta et al. (2014) found that 6-SL inhibits
324 *Pseudomonas aeruginosa* PAK invasion of pneumocytes. Kavanaugh et al. (2013)
325 demonstrated that 6-SL increased adhesion of *Bifidobacterium longum* subsp. *infantis* ATCC
326 15697 to HT-29. Consequently, 6-SL was chosen as an indicator of OS concentration and the

327 concentration of 6-SL in the OSF was matched to levels of 6-SL found in breast milk (0.1 to
328 0.3 mg mL⁻¹; Kunz et al., 2000) when tested on pharynx cells. In fact, this is the potential
329 concentration that an infant's URT would be exposed to during regular breast feeding.

330 The OSF significantly reduced the adhesion of *S. pneumoniae* R6 to the pharynx cells
331 Detroit 562 by 78%, 51% and 25% at OSF concentrations of 6 mg mL⁻¹ (P<0.001), 4 mg mL⁻¹
332 (P<0.001) and 2 mg mL⁻¹ (P<0.001), respectively (Fig. 1). The data demonstrated that the
333 anti-adhesion effect was concentration dependent with the largest anti-adhesive effect seen at
334 the highest physiological concentration tested, 0.3 mg mL⁻¹ (Fig. 1). This suggests that the
335 application of such an OSF should involve the exposure of infants' URT to reported
336 physiological range of HMO. In addition the effect of long term exposure to an OSF should
337 also be considered.

338 The experiment was repeated testing 6 mg mL⁻¹ solutions of demineralised whey and
339 OSP, which are the initial and intermediate material prior to OSF production. Solubility
340 issues meant that higher concentrations could not be tested. In both cases, a minimal (~5%)
341 and not significant reduction of adhesion was observed (Fig. 2). These results suggest that the
342 higher levels of OS present in the OSF were responsible for the observed effect. In fact,
343 demineralised whey, OSP and OSF were tested using the same concentration (6 mg mL⁻¹) of
344 powder, whereas SL concentration increased from 0.003 mg mL⁻¹ in demineralised whey to
345 0.072 mg mL⁻¹ in the OSP to a final 0.3 mg mL⁻¹ in the OSF.

346 The effect of the OSF in reducing the adhesion of *S. pneumoniae* R6 to the lung cell
347 line A549 was also investigated. In this case, concentrations of OSF in the range of 0.24 and
348 2.4 mg mL⁻¹ were used, which correspond to 6-SL concentrations in the range of 0.0125–
349 0.125 mg mL⁻¹. These concentrations were employed for similar studies on *P. aeruginosa*
350 (Marotta et al., 2014) and represent the lowest and highest estimated concentration of the
351 acidic fraction of HMO in infant blood (Bode et al., 2004b), which may potentially reach the

352 lungs. The adhesion of *S. pneumoniae* R6 was significantly reduced by 55, 34 and 17%,
353 following pre-incubation with the OSF at a concentration of 2.4 mg mL⁻¹ ($P < 0.001$), 1.15
354 mg mL⁻¹ ($P < 0.001$) and 0.24 mg mL⁻¹ ($P < 0.005$) (Fig. 3). As the powder was re-suspended
355 in the required media and a control of media alone was included, the effect could be solely
356 attributed to the OS and not to any component in the media.

357 The data reported above is in agreement with Barthelson et al. (1998). In that study,
358 the authors concluded that *S. pneumoniae* relies to a significant extent upon sialylated
359 oligosaccharide ligands terminating in NeuAc α 2-6(or 3)Gal β 1 for adherence to epithelial
360 cells. The predominance of α 2-6 and α 2-3 sialylated oligosaccharides in the OSF, which
361 could act as decoys of the natural receptors of *S. pneumoniae*, could explain the ability of the
362 OSF in reducing *S. pneumoniae* adhesion to respiratory epithelial cells.

363 As the OSF significantly reduced the adhesion of *S. pneumoniae* R6 to the pharynx
364 and lung cells, further studies were carried out to determine if that observed effect was due to
365 the interaction of the OS with the bacteria or epithelial cells. To determine if OS interacted
366 with bacteria, the assay was carried out as described, with the removal of unbound OS prior
367 infection of respiratory epithelial cells. Following the removal of free OS, the adhesion of *S.*
368 *pneumoniae* R6 to pharynx and lung cells was still significantly ($P < 0.001$) reduced by 77%
369 and 48%, respectively (Fig. 4). To determine if the OS interacted with the respiratory
370 epithelial cells, OSF was first incubated with the pharynx and lung cells. Following 30 min
371 incubation, OS were removed and respiratory epithelial cells were infected with *S.*
372 *pneumoniae* R6. No anti-adhesive effect was observed following this modification to the
373 adhesion assay (Fig. 4).

374 The results would indicate that the ability of OS to reduce the adhesion of *S.*
375 *pneumoniae* R6 to epithelial cells of the respiratory tract was mediated by interaction of OS
376 with the bacteria and not with the epithelial cells, in agreement with results observed by

377 Marotta et al. (2014). Furthermore, the results demonstrate that the OSF was not cytotoxic to
378 respiratory epithelial cells, since the adhesion of bacteria to respiratory epithelial cells alone
379 and OSF exposed cells was comparable. Furthermore, the viability of the lung cells making
380 up the confluent monolayer was determined with and without OSF before commencing the
381 adhesion assays to ensure that OSF was not toxic to the A549 cells. The viability was
382 approximately 90% ($P = 0.27$), demonstrating that the growth of the A549 cells was not
383 affected by the exposure to OSF.

384 Taken together, the in vitro results reported in the present study suggest that BMO
385 could be effective in protecting infants from upper and lower respiratory infections associated
386 to *S. pneumoniae*. The precise mechanism of how *S. pneumoniae* establishes and maintains
387 colonisation has yet to be fully characterised. It is clear, however, that the bacterium's
388 glycosidases play a key role in colonisation, as these enzymes are capable of modifying *N*-
389 linked glycans, *O*-linked glycans, and glycosaminoglycans on the host epithelial surface,
390 thereby rendering the host susceptible to colonisation (Bogaert et al., 2004; Tong, Blue,
391 James, & DeMaria, 2000). For instance, NanA cleaves α 2-3- and α 2-6-linked sialic acid,
392 while NanB is specific to α 2-3-linked sialic acid (Gut, King, & Walsh, 2008). Furthermore,
393 BgaA the β -galactosidase is specific to galactose β 1-4 linked to *N*-acetylglucosamine (Gal β 1-
394 4GlcNAc), commonly found in complex *N*-linked glycan structures (King, Hippe, & Weiser,
395 2006; Zähler & Hakenbeck, 2000; Zeleny, Altmann, & Praznik, 1997). It is the modification
396 of the host epithelial surface by these glycosidases that is the first step in bacterial
397 colonisation. As the OSF generated in this study is particularly rich in these structures, it is
398 possible that the anti-adhesive function is due to a decoy effect as has been previously
399 suggested in the literature (Hickey, 2012; Morrow, Ruiz-Palacios, Jiang, & Newburg, 2005;
400 Newburg, 2000).

401

402 5. Conclusions

403

404 This study reports the extraction of BMO in gram quantities from whey, employing a
405 combination of membrane filtration and size-exclusion chromatography. The final product
406 was characterised not only by the presence of predominant sialyllactose, but also by many
407 other sialylated and neutral structures. This product was demonstrated to reduce adhesion of
408 *S. pneumoniae* to pharynx and lungs cells, when it was tested at different physiological
409 concentrations. This study further supports the potential production of value-added
410 ingredients from whey streams, which could be used as functional ingredients in infant
411 formulas and, more broadly, in foods with health benefits.

412

413 Acknowledgements

414

415 The work described herein is supported by Enterprise Ireland under Grant Number
416 CC20080001. The funding body had no involvement in the preparation of this article. The
417 authors thank University of California, Davis for kindly agreeing to the use of OSP and
418 relating results for research purposes including this study, and Simone Albrecht (National
419 Institute for Bioprocessing Research & Training, Dublin, Ireland) for HILIC analyses.

420

421 References

422

423 Altmann, K., Wutkowski, A., Kämpfer, S., Klempt, M., Lorenzen, P. C., &

424 Clawin-Radecker, I. (2015). Comparison of the efficiency of different NF membranes
425 for the enrichment of milk oligosaccharides from bovine milk. *European Food*
426 *Research and Technology*, 241, 803–815.

- 427 Andersson, B., & Svanborg-Eden, C. (1989). Attachment of *Streptococcus pneumoniae* to
428 human pharyngeal epithelial cells. *Respiration*, 55, 49–52.
- 429 Bachrach, V. R. G., Schwarz, E., & Bachrach, L. R. (2003). Breastfeeding and the risk of
430 hospitalization for respiratory disease in infancy. *Archives of Pediatrics and*
431 *Adolescent Medicine*, 157, 237–243.
- 432 Barile, D., Tao, N., Lebrilla, C. B., Coisson, J. D., Arlorio, M., & German, J. B. (2009).
433 Permeate from cheese whey ultrafiltration is a source of milk oligosaccharides.
434 *International Dairy Journal*, 19, 524–530.
- 435 Barthelson, R., Mobasser, A., Zopf, D., & Simon, P. (1998). Adherence of *Streptococcus*
436 *pneumoniae* to respiratory epithelial cells is inhibited by sialylated oligosaccharides.
437 *Infection and Immunity*, 66, 1439–1444.
- 438 Bode, L., Kunz, C., Muhly-Reinholz, M., Mayer, K., Seeger, W., & Rudloff, S. (2004a).
439 Inhibition of monocyte, lymphocyte, and neutrophil adhesion to endothelial cells by
440 human milk oligosaccharides. *Thrombosis and Haemostasis*, 92, 1402–1410.
- 441 Bode, L., Rudloff, S., Kunz, C., Strobel, S., & Klein, N. (2004b). Human milk
442 oligosaccharides reduce platelet-neutrophil complex formation leading to a decrease
443 in neutrophil β 2 integrin expression. *Journal of Leukocyte Biology*, 76, 820–826.
- 444 Bogaert, D., de Groot, R., & Hermans, P. W. M. (2004). *Streptococcus pneumoniae*
445 colonisation: the key to pneumococcal disease. *Lancet Infectious Diseases*, 4, 144–
446 154.
- 447 Bosch, A. A., Biesbroek, G., Trzcinski, K., Sanders, E. A., & Bogaert, D. (2013). Viral and
448 bacterial interactions in the upper respiratory tract. *PLoS Pathogens*, 9, Article
449 e1003057.

- 450 Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of microgram
451 quantities of protein utilizing the principle of protein-dye binding. *Analytical*
452 *Biochemistry*, 72, 248–254.
- 453 Cohen, J. L., Barile, D., Liu, Y., & de Moura Bell, J. M. L. N. (2017). Role of pH in the
454 recovery of bovine milk oligosaccharides from colostrum whey permeate by
455 nanofiltration. *International Dairy Journal*, 66, 68–75.
- 456 Duijts, L., Ramadhani, M. K., & Moll, H.A. (2009). Breastfeeding protects against infectious
457 diseases during infancy in industrialized countries. A systematic review. *Maternal*
458 *and Child Nutrition*, 5, 199–210.
- 459 Eiwegger, T., Stahl, B., Haidl, P., Schmitt, J., Boehm, G., Dehlink, E., et al. (2010). Prebiotic
460 oligosaccharides: in vitro evidence for gastrointestinal epithelial transfer and
461 immunomodulatory properties. *Pediatric Allergy and Immunology*, 21, 1179–1188.
- 462 García-Rodríguez, J. Á., & Martínez, M. J. F. (2002). Dynamics of nasopharyngeal
463 colonization by potential respiratory pathogens. *Journal of Antimicrobial*
464 *Chemotherapy*, 50, 59–74.
- 465 Gartner, L. M., Morton, J., Lawrence, R. A., Naylor, A. J., O'Hare, D., Schanler, R. J., et al.
466 (2005). Breastfeeding and the use of human milk. *Pediatrics*, 115, 496–506.
- 467 Goehring, K. C., Kennedy, A. D., Prieto, P. A., & Buck, R. H. (2014). Direct evidence for the
468 presence of human milk oligosaccharides in the circulation of breastfed infants. *PloS*
469 *one*, 9, Article e101692.
- 470 Gut, H., King, S. J., & Walsh, M. A. (2008). Structural and functional studies of
471 *Streptococcus pneumoniae* neuraminidase B: An intramolecular trans-sialidase. *FEBS*
472 *Letters*, 582, 3348–3352.
- 473 Hickey, R. M. (2012). The role of oligosaccharides from human milk and other sources in
474 prevention of pathogen adhesion. *International Dairy Journal*, 22, 141–146.

- 475 Idänpään-Heikkilä, I., Simon, P. M., Zopf, D., Vullo, T., Cahill, P., & Sokol, K. (1997).
476 Oligosaccharides interfere with the establishment and progression of experimental
477 pneumococcal pneumonia. *Journal of Infectious Diseases*, *176*, 704–712.
- 478 Jensch, I., Gámez, G., Rothe, M., Ebert, S., Fulde, M., Somplatzki, D., et al. (2010). PavB is
479 a surface-exposed adhesin of *Streptococcus pneumoniae* contributing to
480 nasopharyngeal colonization and airways infections. *Molecular Microbiology*, *77*, 22–
481 43.
- 482 Kallio, A., Sepponen, K., Hermand, P., Denoël, P., Godfroid, F., & Melin, M. (2014). Role of
483 Pht proteins in attachment of *Streptococcus pneumoniae* to respiratory epithelial cells.
484 *Infection and Immunity*, *82*, 1683–1691.
- 485 Kavanaugh, D. W., O'Callaghan, J., Buttó, L. F., Slattery, H., Lane, J., Clyne, M., et al.
486 (2013). Exposure of *Bifidobacterium longum* subsp. *infantis* to milk oligosaccharides
487 increases adhesion to epithelial cells and induces a substantial transcriptional
488 response. *PloS One*, *8*, Article e67224.
- 489 King, S. J., Hippe, K. R., & Weiser, J. N. (2006). Deglycosylation of human glycoconjugates
490 by the sequential activities of exoglycosidases expressed by *Streptococcus*
491 *pneumoniae*. *Molecular Microbiology*, *59*, 961–974.
- 492 Kunz, C., Rudloff, S., Baier, W., Klein, N., & Strobel, S. (2000). Oligosaccharides in human
493 milk: structural, functional, and metabolic aspects. *Annual Review of Nutrition*, *20*,
494 699–722.
- 495 Mariño, K., Lane, J. A., Abrahams, J. L., Struwe, W. B., Harvey, D. J., Marotta, M., et al.
496 (2011). Method for milk oligosaccharide profiling by 2-aminobenzamide labeling and
497 hydrophilic interaction chromatography. *Glycobiology*, *21*, 1317–1330.

- 498 Marotta, M., Ryan, J. T., & Hickey, R. M. (2014). The predominant milk oligosaccharide 6'-
499 sialyllactose reduces the internalisation of *Pseudomonas aeruginosa* in human
500 pneumocytes. *Journal of Functional Foods*, 6, 367–373.
- 501 Mehra, R., Barile, D., Marotta, M., Lebrilla, C. B., Chu, C., & German, J. B. (2014). Novel
502 high-molecular weight fucosylated milk oligosaccharides identified in dairy streams.
503 *PloS One*, 9, Article e96040.
- 504 Morrow, A. L., Ruiz-Palacios, G. M., Jiang, X., & Newburg, D. S. (2005). Human-milk
505 glycans that inhibit pathogen binding protect breast-feeding infants against infectious
506 diarrhea. *Journal of Nutrition*, 135, 1304–1307.
- 507 Newburg, D. S. (2000). Oligosaccharides in human milk and bacterial colonization. *Journal*
508 *of Pediatric Gastroenterology and Nutrition*, 30, S8-S17.
- 509 Pettigrew, M. M., Gent, J. F., Revai, K., Patel, J. A., & Chonmaitree, T. (2008). Microbial
510 interactions during upper respiratory tract infections. *Emerging Infectious Diseases*,
511 14, 1584–1592.
- 512 Rosenow, C., Ryan, P., Weiser, J. N., Johnson, S., Fontan, P., Ortqvist, A., et al. (1997).
513 Contribution of novel choline-binding proteins to adherence, colonization and
514 immunogenicity of *Streptococcus pneumoniae*. *Molecular Microbiology*, 25, 819–
515 829.
- 516 Rudan, I., Boschi-Pinto, C., Biloglav, Z., Mulholland, K., & Campbell, H. (2008).
517 Epidemiology and etiology of childhood pneumonia. *Bulletin of the World Health*
518 *Organization*, 86, 408–416.
- 519 Stepans, M. B. F., Wilhelm, S. L., Hertzog, M., Rodehorst, T. K. C., Blaney, S., Clemens, B.,
520 et al. (2006). Early consumption of human milk oligosaccharides is inversely related
521 to subsequent risk of respiratory and enteric disease in infants. *Breastfeeding*
522 *Medicine*, 1, 207–215.

- 523 Tong, H., McIver, M., Fisher, L., & DeMaria, T. (1999). Effect of lacto-N-neotetraose,
524 asialoganglioside-GM1 and neuraminidase on adherence of otitis media-associated
525 serotypes of *Streptococcus pneumoniae* to chinchilla tracheal epithelium. *Microbial*
526 *Pathogenesis*, 26, 111–119.
- 527 Tong, H. H., Blue, L. E., James, M. A., & DeMaria, T. F. (2000). Evaluation of the virulence
528 of a *Streptococcus pneumoniae* neuraminidase-deficient mutant in nasopharyngeal
529 colonization and development of otitis media in the chinchilla model. *Infection and*
530 *Immunity*, 68, 921–924.
- 531 Urashima, T., Messer, M., & Oftedal, O. T. (2017). Oligosaccharides in the milk of other
532 mammals. In M. K. McGuire, M.A. McGuire & L. Bode (Eds.), *Prebiotics and*
533 *probiotics in human milk* (pp 45–139). London, UK: Elsevier Inc.
- 534 Varki, A., & Marth, J. (1995). Oligosaccharides in vertebrate development. *Seminars in*
535 *Developmental Biology*, 6, 127–138.
- 536 Varki, A., & Schauer, R. (2009). Sialic acids. In A. Varki, R. D. Cummings, J. D. Esko, H. H.
537 Freeze, P. Stanley, C. R. Bertozzi, et al. (Eds.) *Essentials of glycobiology* (2nd edn.,
538 Chapt. 14). Cold Spring Harbor, NY, USA: Cold Spring Harbor Laboratory Press.
- 539 Wright, A. L., Holberg, C. J., Martinez, F. D., Morgan, W. J., & Taussig, L. M. (1989).
540 Breast feeding and lower respiratory tract illness in the first year of life. Group Health
541 Medical Associates. *British Medical Journal*, 299, 946–949.
- 542 Zähler, D., & Hakenbeck, R. (2000). The *Streptococcus pneumoniae* β -galactosidase is a
543 surface protein. *Journal of Bacteriology*, 182, 5919–5921.
- 544 Zeleny, R., Altmann, F., & Praznik, W. (1997). A capillary electrophoretic study on the
545 specificity of β -galactosidases from *Aspergillus oryzae*, *Escherichia coli*,
546 *Streptococcus pneumoniae*, and *Canavalia ensiformis* (Jack Bean). *Analytical*
547 *Biochemistry*, 246, 96–101.

1 **Figure legends**

2

3 **Fig. 1.** Effect of concentration of the oligosaccharide-enriched fraction (OSF) on *S.*
4 *pneumoniae* R6 adhesion to Detroit 562 pharynx cells; control (CNT) was *S. pneumoniae* R6
5 in the absence of saccharide. Data are means \pm standard deviation of assays carried out on
6 three separate occasions in triplicate; an asterisk indicates $P < 0.001$.

7

8 **Fig. 2.** Effect of different substrates on interaction of *S. pneumoniae* R6 on pharynx cells.
9 *S. pneumoniae* R6 was incubated with 6 mg mL⁻¹ of demineralised whey powder (DWP),
10 oligosaccharide-enriched powder (OSP) and oligosaccharide-enriched fraction (OSF) in
11 EMEM supplemented with 2% FBS (v/v); control (CNT) was performed with no saccharide.
12 Data are means \pm standard deviation of assays carried out in triplicate; an asterisk indicates P
13 < 0.001 .

14

15 **Fig. 3.** Effect of concentration of the OSF on *S. pneumoniae* R6 adhesion to A549 lung cells;
16 control (CNT) was *S. pneumoniae* R6 in the absence of saccharide. Data are means \pm
17 Standard deviation of assays carried out on three separate occasions in triplicate; an asterisk
18 indicates $P < 0.005$.

19

20 **Fig. 4.** Interaction of oligosaccharide-enriched fraction (OSF) with *S. pneumoniae* R6 (■) or
21 with eukaryotic cells (■). Left-hand set of data: *S. pneumoniae* R6 was incubated with 6 mg
22 mL⁻¹ of OSF in EMEM supplemented with 2% FBS. After incubation the unbound
23 oligosaccharides were removed before the bacteria were used to infect the pharynx cell (■).
24 Pharynx cells were incubated with 6 mg mL⁻¹ of OSF in the medium above. The unbound
25 OSF was removed from the pharynx cells, which were subsequently infected with *S.*

26 *pneumoniae* R6 (■). An asterisk indicates $P < 0.001$. Control (□, pharynx cells) was
27 performed with no saccharide. Right-hand set of data: *S. pneumoniae* R6 was incubated with
28 2.4 mg mL^{-1} of OSF in DMEM supplemented with 2% FBS. After incubation the unbound
29 oligosaccharides were removed before the bacteria were used to infect the eukaryotic cells
30 (■). Lung cells were incubated with 2.4 mg mL^{-1} OSF in the above medium. The unbound
31 OSF was removed from the lung cells, which were subsequently infected with *S. pneumoniae*
32 R6 (■). An asterisk indicates $P < 0.001$. Control (CNT, lung cells) was performed with no
33 saccharide.

Table 1

Enrichment of oligosaccharides from OSP employing size exclusion chromatography. ^a















Oligosaccharide	OSP	OSF	Yield (%)
Lactose (g, total)	149.628	0.079	0.05
SL (g, total)	2.9175	2.084	71.43








^a Abbreviations are: OSP, oligosaccharides-rich powder; OSF, oligosaccharides-rich fraction.

Seven hundred and fifty millilitres of OSP were applied over 15 runs and 8.83 g of OSF were recovered pooling fractions from the 15 runs.

Table 2

Structural assignment of oligosaccharides in oligosaccharides-rich fraction (OSF).

Peak number	m/z observed	m/z theoretical	UXOF Symbol structural assignment	GU value	Relative % UPLC-HILIC-FLD
1	-	-	monosaccharides	1.00	-
2	-	-		1.03	-
3	502.22	502.20		1.88	0.7
4	461.21	461.18		1.95	2.5
5	-	-	neutral di- or tri-saccharides	2.28	-
6	-	-	acidic di- or tri-saccharides	2.33	0.1
7	-	-		2.36	0.02
8	607.27	607.24		2.49	0.7
	794.32	794.28			
9	664.29	664.26		2.71	23.8
10	664.29	664.26		2.83	1.3
11	623.26	623.23		2.89	1.3
12	623.26	623.23		2.98	9.6
13	752.31	752.27	major component: 	3.15	47.8
	623.26	623.23	minor component: 		
14	-	-	acidic tri- or tetrasaccharides	3.30	0.2
15	-	-		3.34	0.1
16	-	-		3.38	0.1
17	793.35	793.30		3.48	0.7
18	768.30	768.27		3.50	0.4
19	752.31	752.27		3.56	7.4
20	826.36	826.31		3.63	0.6

21	1085.47	1085.38	Ac 	3.84	0.1
22	955.39	955.35		3.91	0.3
23	914.37	914.33		4.01	1.3
24	-	-	acidic oligosaccharide	4.11	0.03
25	914.37	914.33		4.33	0.2
26	1043.44	1043.37		4.58	0.4
27	1029.45	1029.39		4.69	-
28	988.43	988.36		4.84	0.1
29	-	-	acidic oligosaccharide	5.47	0.2

^a Relative % UPLC-HILIC-FLD represents area of peaks compared with total peak area in HILIC chromatograms. Symbols are: ■, *N*-acetylglucosamine; □, glucose; ◇, galactose; ◆, *N*-acetylgalactosamine; ◇, fucose; ○, mannose; ★, *N*-acetylneuraminic acid; ☆, *N*-glycolylneuraminic acid; △, xylose. Linkages are denoted as: ---, α -linkage; —, β -linkage.




Figure 1.




Figure 2.




Figure 3.




Figure 4.